Polyoxidonium

NPO Petrovax Concludes Pivotal Phase 3 Trial for Polyoxidonium in Pediatric Acute Respiratory Infections

NPO Petrovax has completed its pivotal Phase 3 clinical trial (NCT03840135) for Polyoxidonium nasal and sublingual spray, 6 mg/ml, targeting Acute Respiratory Infections (ARI) in children aged 1-12 years. This development signals potential market entry for a non-FDA regulated treatment, requiring procurement and regulatory teams to assess its commercial viability and regional regulatory pathways, particularly for pediatric ARI management.